All neuropathologically confirmed cases of variant CreutzfeldtJakob disease (vCJD), characterized by abundant florid plaques and type 4 disease-related prion protein (PrP Sc ) in the brain, have been homozygous for methionine at polymorphic residue 129 of PRNP. The distinctive neuropathological and molecular phenotype of vCJD can be faithfully recapitulated in Prnp-null transgenic mice homozygous for human PrP M129 but not V129, where a distinct prion strain is propagated. Here we model susceptibility of 129MV heterozygotes, the most common PRNP genotype, in transgenic mice and show that, remarkably, propagation of type 4 PrP Sc was not associated with characteristic vCJD neuropathology. Depending on the source of the inoculum these mice can develop four distinct disease phenotypes after challenge with bovine spongiform encephalopathy (BSE) prions or vCJD (human-passaged BSE) prions. vCJD-challenged mice had higher attack rates of prion infection than BSE-challenged recipients. These data argue that human PRNP 129 heterozygotes will be more susceptible to infection with vCJD prions than to cattle BSE prions and may present with a neuropathological phenotype distinct from vCJD.
A
ccording to the ''protein-only'' hypothesis (1), prions are composed principally or entirely of abnormal isoforms of host-encoded prion protein (PrP) (2, 3) . The disease-related isoform, PrP Sc , is derived from its normal cellular precursor, PrP C , by a posttranslational process that involves conformational change. PrP Sc can be distinguished biochemically from PrP C by its partial resistance to proteolysis and detergent insolubility (2, 3) . Multiple prion strains are recognized, and these are associated with distinct PrP Sc types that can be distinguished by Western blot analysis with distinct cleavage sites to proteinase K implying different PrP Sc conformations (4) (5) (6) (7) (8) and by differences in the glycoform ratios of protease-digested PrP Sc (5, 8) .
The appearance of a novel human prion disease, variant Creutzfeldt-Jakob disease (vCJD), in the United Kingdom from 1995 onwards (9) , and the experimental confirmation that this is caused by the same prion strain as that causing bovine spongiform encephalopathy (BSE) in cattle (5, (10) (11) (12) , has led to widespread concern that exposure to the epidemic of BSE poses a distinct and conceivably a severe threat to public health in the United Kingdom and other countries (13) . The extremely prolonged and variable incubation periods seen with prion diseases when crossing a species barrier means that it will be some years before the parameters of any human epidemic can be predicted with confidence (13) (14) (15) . In the meantime, we are faced with the possibility that significant numbers in the population may be incubating this disease and that they might pass it on to others through blood transfusion, blood products, tissue and organ transplantation, and other iatrogenic routes (13, (16) (17) (18) .
To date, the clinical presentation of human BSE infection has only been recognized as vCJD in individuals homozygous for methionine at polymorphic residue 129 of human PrP. The neuropathological features of vCJD are highly distinct from those seen in classical (sporadic or iatrogenic) CreutzfeldtJakob disease (CJD) and are characterized by the presence of abundant f lorid PrP plaques (9) and the propagation of type 4 disease-related PrP Sc in brain (5) . Polymorphism at codon 129 of the human PrP gene (PRNP), where either methionine (M) or valine (V) can be encoded, powerfully affects susceptibility to human prion diseases. Homozygotes have increased susceptibility to either sporadic CJD (19) or acquired prion diseases (20 -22) , and homozygosity or heterozygosity at codon 129 may affect age at onset in inherited prion disease (19, (23) (24) (25) . We have previously described four human PrP Sc types in brain tissue from patients with CJD: types 1-3 are seen in classical CJD, and type 4 is uniquely seen in vCJD (5, 8, 26) . Polymorphism at residue 129 appears to place constraints on the propagation of human PrP Sc types. To date, types 1 and 4 PrP Sc have been found only in humans of the MM genotype, type 3 PrP Sc is seen almost exclusively in individuals with at least one valine allele, and type 2 PrP Sc has been commonly observed in all codon 129 genotypes (5, 8, 26) . Transgenic modeling of BSE and vCJD prion infection in mice expressing human, but not mouse, PrP (5, 10, 12, 27) indicates that this polymorphism directly dictates the propagation of distinct PrP Sc conformers, consistent with a conformational selection model of prion transmission barriers (3, 13, 27, 28) .
Notably, there appear to be no overlapping preferred PrP Sc conformations for V129 and M129 human PrP that can be generated as a result of exposure to the vCJD͞BSE prion strain (27) . Depending on the origin of the inoculum and the PrP codon 129 genotype of the host, transmission of cattle BSE prions or vCJD (human-passaged BSE) prions can result in four distinct prion disease phenotypes. Transgenic mice homozygous for human PrP M129 propagate either type 2 or 4 PrP Sc with respective neuropathologies consistent with human sporadic CJD or vCJD (12, 27) , whereas transgenic mice homozygous for human PrP V129 either propagate type 5 PrP Sc and a distinct pattern of neuropathology or develop clinical prion disease in the absence of detectable PrP Sc (10, 27) . These findings argue that primary BSE prion infection, as well as secondary infection by iatrogenic routes, may not be restricted to a single disease phenotype in humans with PRNP homozygous genotypes. Here we now report analysis of transgenic mice expressing both human PrP M129 and V129 to model susceptibility of the commonest human PRNP genotype, 129MV heterozygotes, comprising 51% of the United Kingdom population (21, 29) .
Results and Discussion
We generated human PrP 129MV heterozygous transgenic mice by crossing two previously well characterized transgenic lines, 129MM Tg45 mice (12) and 129VV Tg152 mice (5, 10, 27, 30) . Human PrP 129MV heterozygous mice, designated 129MV Tg45͞152, express human PrP M129 and V129 at similar levels (ratio Ϸ1:1.5) with a total PrP expression level in the brain comparable to each parental transgenic line (at Ϸ4-to 6-fold level of pooled normal human brain) (data not shown). These lines were all on a Prnp o/o background and therefore expressed human, but not mouse, PrP.
After challenge with a panel of human and bovine prion isolates characterized previously (5, 10, 12, 27) , we found that sporadic or iatrogenic CJD prions, from patients of all three PRNP 129 genotypes, transmitted with high clinical attack rates to 129MV Tg45͞152 mice (Table 1) . Although clinical prion disease was not observed in all prion-infected mice (Table 1) , infected recipients that lacked the typical clinical signs of prion disease had abundant PrP Sc in the brain and generally died at postinoculation intervals very close to the group mean incubation periods (Table 1 ). In contrast, mock-inoculated 129MV Tg45͞152 mice survived to advanced age without clinical or neuropathological signs of prion disease or detectable PrP Sc (data not shown).
Remarkably, a 100% infection rate was seen in vCJD prioninoculated 129MV Tg45͞152 mice ( Fig. 1 and Table 1 ), but without clinical signs of prion disease (subclinical infection), and in 14͞15 of these mice we readily detected type 4 PrP Sc in brain ( Fig. 2A) . However, although type 4 PrP Sc is faithfully propagated in 129MV Tg45͞152 mice, the associated neuropathology was completely distinct from vCJD. Abundant florid plaques are the neuropathological hallmark of vCJD and to date have been found only in association with BSE or vCJD prion infection in hosts with PrP M129 homozygosity (in humans, primates, or transgenic mice) (9, 12, 27, 31) . In contrast, type 4 PrP Sc propagation in 129MV Tg45͞152 mice was associated with large nonflorid PrP plaques in the corpus callosum ( Fig. 3D ) accompanied by diffuse synaptic PrP deposition and occasional small nonflorid PrP plaques in the brainstem and thalamus (Fig. 3G ). Spongiform neurodegeneration was observed only at moderate levels in the cerebellum, brainstem, and thalamus ( Fig. 3 A and J). Despite an exhaustive search, only a single PrP florid plaque was found in the brain of one 129MV Tg45͞152 mouse propagating type 4 PrP Sc (Fig. 4A) . Importantly, the absence of florid plaques in the brain of vCJD-inoculated 129MV Tg45͞152 mice is not due to a lack of PrP C expression in the cerebral cortex. Challenge of these mice or the two parental lines (129MM Tg45 and 129VV Tg152 mice) with sporadic CJD isolate I024 produced 100% clinical disease in all lines, with significant spongiosis and typical diffuse synaptic PrP deposition throughout the cerebral cortex and other brain areas (data not shown). Overexpression of PrP M129 in transgenic mouse brain also does not seem to be a prerequisite for generation of florid PrP plaques on challenge with BSE or vCJD prions. We also observed abundant florid PrP plaques in vCJD-inoculated 129MM Tg28 mice, a transgenic line expressing endogenous levels of human PrP M129 (Fig. 4 B and C) . Based on these findings we propose that, in the heterozygous state in 129MV Tg45͞152 mice, PrP V129 may have a dominant negative effect on florid PrP plaque formation. Because we saw no evidence for recruitment of PrP V129 to type 5 PrP Sc in vCJD-inoculated 129MV Tg45͞152 mice, one possibility is that PrP V129 acts to slow the rate of conversion of PrP M129 to type 4 PrP Sc and that this prevents the evolution of florid PrP plaques leading to the uncoupling of vCJD neu- ropathology from propagation of type 4 PrP
Sc . This interpretation is consistent with findings from other transgenic studies showing that the kinetics of PrP Sc propagation from one allelic variant of PrP can be dramatically affected by coexpression of nonhomologous PrP (30, 32, 33) .
The absence of type 5 PrP Sc in vCJD-inoculated 129MV Tg45͞152 mice is consistent with our previous work indicating that the vCJD prion strain propagates most efficiently from human PrP M129 (with faithful replication of type 4 PrP Sc ) (12, 27) , whereas a substantial barrier limits propagation of type 5 PrP Sc from human PrP V129 (10, 27) . This interpretation was reinforced by direct investigation of the transmission properties of type 5 PrP Sc in 129MV Tg45͞152 mice (Table 1 and Fig. 1 ). Here we observed the presence of a substantial transmission barrier, and, in contrast to type 4 PrP Sc , type 5 PrP Sc did not uniformly breed true in 129MV Tg45͞152 mice ( Fig. 1 and Table  1 ). Although 10͞12 inoculated mice showed evidence of prion infection, in five subclinically affected mice PrP neuropathology was absent, and high-sensitivity methods (16) were required to demonstrate PrP Sc in brain ( Fig. 1 and Table 1 ). Although the method used precluded accurate molecular typing of this PrP Sc (16) (Fig. 1) in 129VV Tg152 mice (27) with PrP deposition restricted to nonflorid PrP plaques in the corpus callosum (Fig. 3 B and E) . However, in distinction to 129VV Tg152 mice, no significant spongiosis was detectable throughout the brain (Fig. 3 B and K) . In sharp contrast, type 2 Ϫ PrP Sc was associated with widespread spongiosis in the cortex, hippocampus, thalamic nuclei, and tectum (Fig. 3C) , and extensive synaptic PrP deposition was seen in the thalamus in addition to nonflorid PrP plaques in the corpus callosum (Fig. 3 C and F) . The PrP deposits in the corpus callosum were extracellular, and we did not observe any significant PrP-immunoreactive deposits around blood vessels in any part of the brain examined.
The presence of a substantial transmission barrier and evidence for propagation of distinct prion strain types were also observed after primary transmission of BSE prions to 129MV Tg45͞152 mice ( Fig. 1 and Table 1 ). Here only 12͞41 BSEinoculated mice showed evidence of prion infection, and none of the affected mice showed abnormal PrP immunohistochemistry. Nine affected 129MV Tg45͞152 mice developed clinical signs of prion disease in the absence of detectable PrP Sc ( Fig. 1 and Table  1 ) similar to primary transmission of BSE prions in 129VV Tg152 mice (10) . However, in the absence of abnormal PrP immunohistochemistry or immunoblotting it will be crucial to confirm transmission by secondary passage. Nonetheless, in this regard we previously demonstrated that PrP Sc -negative brain isolates from clinically affected BSE-challenged 129VV Tg152 mice transmit clinical prion disease accompanied by abundant PrP Sc accumulation when inoculated in wild-type FVB mice (27) . Thus, clinical prion disease in the absence of detectable PrP Sc is an expected phenotype associated with the interaction of BSE prions and human PrP V129. Notably, the absence of detectable PrP Sc has also been observed in clinically affected BSEchallenged wild-type mice (34) .
In the other three affected BSE-inoculated 129MV Tg45͞152 mice we detected sporadic CJD-like PrP Sc with a predominance of monoglycosylated PrP (Fig. 2C ) similar to findings from primary transmission of BSE prions to 129MM Tg35 mice (12) . Collectively, these data suggest that prion propagation from human PrP M129 or V129 is possible in BSE-challenged 129MV Tg45͞152 mice. However, we found no evidence for propagation of type 4 PrP Sc or associated vCJD-like neuropathology in these transmissions. Although caution must be exercised in extrapolating from animal models [even where faithful recapitulation of molecular and pathological phenotypes is possible (12, 27) ], our findings suggest that human PRNP codon 129 heterozygotes will be susceptible to infection with human-passaged BSE (vCJD) prions but may be less susceptible to primary infection with BSE prions. Depending on the source of the inoculum, multiple disease phenotypes appear possible. Neuropathologically, none of these phenotypes may resemble vCJD, because in the PrP codon 129MV genotype the propagation of type 4 PrP Sc is dissociated from the occurrence of abundant florid PrP plaques. These findings underline the need for continued surveillance and investigation of all forms of human prion disease within the United Kingdom and in other populations with extensive dietary exposure to BSE prions. Transmission Studies. All procedures were carried out in a microbiological containment level III facility with strict adherence to safety protocols. Inocula were prepared by using disposable equipment for each inoculum, and inoculations were performed within a class 1 microbiological safety cabinet. BSE tissues were collected under strict aseptic conditions using sterile instrumentation specifically for transmission studies by the United Kingdom Central Veterinary Laboratory (now the Veterinary Laboratories Agency). Four separate BSE inocula, derived from the brainstem of four natural BSE cases (I060, I062, I064, and I066), were studied, together with a pool of brainstems from five natural BSE cases (I038). The BSE pool homogenate (I038) was titrated in RIII wild-type mice at the Veterinary Laboratories Agency and had a titer of 10 3.3 mouse intracerebral LD 50 units per gram of tissue. These BSE isolates have been used in previous transmission studies (10, 12, 30) . Inocula were prepared from the brain of neuropathologically confirmed cases of sporadic CJD and vCJD with consent from relatives and with approval from the Institute of Neurology͞National Hospital for Neurology and Neurosurgery Local Research Ethics Committee. Before inoculation the genotype of each transgenic mouse was confirmed by PCR of tail DNA, and all mice were uniquely identified by s.c. transponders. Disposable cages were used, and all cage lids and water bottles were also uniquely identified by transponder and remained with each cage of mice throughout the incubation period. Care of the mice was according to institutional guidelines. Both transgenic and wild-type mice were anesthetized with a mixture of halothane and O 2 and intracerebrally inoculated into the right parietal lobe with 30 l of a 1% wt͞vol brain homogenate prepared in PBS. All mice were thereafter examined daily for clinical signs of prion disease. Mice were killed if exhibiting any signs of distress or once a diagnosis of prion disease was established. The criteria for clinical diagnosis of prion disease in mice were as described in ref. 37 .
Materials and Methods
Neuropathology and Immunohistochemistry. Mice were killed by CO 2 asphyxiation. Brains were fixed in 10% buffered formol saline and then immersed in 98% formic acid for 1 h and paraffin wax-embedded. Serial sections of 4-m thickness were pretreated by boiling for 10 min in a low-ionic-strength buffer (2.1 mM Tris͞1.3 mM EDTA͞1.1 mM sodium citrate, pH 7.8) before exposure to 98% formic acid for 5 min. Abnormal PrP accumulation was examined by using anti-PrP monoclonal antibody ICSM 35 (D-Gen, London) on a Ventana automated immunohistochemical staining machine (Ventana Medical Systems, Tucson) by using proprietary secondary detection reagents (Ventana Medical Systems) before development with 3Ј3 diaminobenzedine tetrachloride as the chromogen. Harris hematoxylin and eosin staining was done by conventional methods. Appropriate controls were used throughout.
Immunoblotting. Ten percent wt͞vol brain homogenates were prepared in Dulbecco's PBS (lacking Ca 2ϩ or Mg 2ϩ ) by serial passage through needles of decreasing diameter. Proteinase K digestion (100 g͞ml final protease concentration, 1 h, 37°C), electrophoresis, and immunoblotting were performed as described in ref. 16 . Blots were blocked in PBS containing 0.05% vol͞vol Tween 20 and 5% wt͞vol nonfat milk powder and then probed with anti PrP monoclonal antibody 3F4 (38) in conjunction with an alkaline phosphatase-conjugated secondary antibody and chemiluminescent substrate CDP-Star (Tropix) as described (16) . Brain homogenates scored negative for PrP Sc after analysis of 10 l of 10% brain homogenate were reanalyzed by sodium phosphotungstic acid precipitation of PrP Sc from 250 l of 10% brain homogenate as described (16) . After recovery of PrP Sc by sodium phosphotungstic acid and proteinase K digestion, distinction of differences in glycoform ratios of the three principal amino-terminally truncated PrP fragments is possible; however, this method is not compatible with accurate PrP Sc fragment size analysis used in characterization of prion strain types (16) .
We thank C. Brown and his team for animal care, M.-W. Burley for technical assistance, and R. Young for preparation of the figures. We especially thank all patients and their families for generously consenting to use of human tissues in this research and the United Kingdom neuropathologists who kindly helped in providing these tissues. We thank R. Bradley, D. Matthews, S. A. C. Hawkins, and colleagues at the United Kingdom Veterinary Laboratories Agency for providing BSE tissues. This research was supported by the Medical Research Council (United Kingdom) and the European Commission.
